HK1207389A1 - Fc containing polypeptides with altered glycosylation and reduced effector function fc - Google Patents

Fc containing polypeptides with altered glycosylation and reduced effector function fc

Info

Publication number
HK1207389A1
HK1207389A1 HK15108040.6A HK15108040A HK1207389A1 HK 1207389 A1 HK1207389 A1 HK 1207389A1 HK 15108040 A HK15108040 A HK 15108040A HK 1207389 A1 HK1207389 A1 HK 1207389A1
Authority
HK
Hong Kong
Prior art keywords
effector function
containing polypeptides
altered glycosylation
reduced effector
glycosylation
Prior art date
Application number
HK15108040.6A
Other languages
English (en)
Chinese (zh)
Inventor
Clark Pan
Huawei Qiu
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50278674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1207389(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/003819 external-priority patent/WO2013037484A2/en
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of HK1207389A1 publication Critical patent/HK1207389A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
HK15108040.6A 2012-09-12 2015-08-19 Fc containing polypeptides with altered glycosylation and reduced effector function fc HK1207389A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/003819 WO2013037484A2 (en) 2011-09-12 2012-09-12 Anti-aplhabetatcr antibody
US201361776715P 2013-03-11 2013-03-11
PCT/US2013/059481 WO2014043361A1 (en) 2012-09-12 2013-09-12 Fc containing polypeptides with altered glycosylation and reduced effector function

Publications (1)

Publication Number Publication Date
HK1207389A1 true HK1207389A1 (en) 2016-01-29

Family

ID=50278674

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108040.6A HK1207389A1 (en) 2012-09-12 2015-08-19 Fc containing polypeptides with altered glycosylation and reduced effector function fc

Country Status (35)

Country Link
EP (3) EP4223783A3 (el)
JP (1) JP6438397B2 (el)
KR (3) KR20220110855A (el)
CN (2) CN104797601B (el)
AU (1) AU2013315499B2 (el)
CA (1) CA2884762C (el)
CL (1) CL2015000606A1 (el)
CR (1) CR20150147A (el)
CY (1) CY1120909T1 (el)
DK (2) DK2895513T3 (el)
DO (1) DOP2015000050A (el)
EA (2) EA035987B1 (el)
EC (1) ECSP15014133A (el)
ES (2) ES2950509T3 (el)
FI (1) FI3366705T3 (el)
HK (1) HK1207389A1 (el)
HR (2) HRP20230623T1 (el)
HU (2) HUE062876T2 (el)
IL (4) IL237640B (el)
LT (2) LT3366705T (el)
MA (1) MA37949B1 (el)
MX (2) MX366103B (el)
MY (1) MY170126A (el)
NZ (1) NZ705983A (el)
PE (1) PE20150650A1 (el)
PH (1) PH12015500528A1 (el)
PL (2) PL2895513T3 (el)
PT (2) PT3366705T (el)
RS (2) RS64317B1 (el)
SG (2) SG11201501521TA (el)
SI (2) SI2895513T1 (el)
TN (1) TN2015000085A1 (el)
UA (1) UA116995C2 (el)
WO (1) WO2014043361A1 (el)
ZA (1) ZA201501417B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
CA2902530C (en) 2013-03-11 2023-05-09 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
EP4015535A1 (en) * 2014-03-19 2022-06-22 Genzyme Corporation Site-specific glycoengineering of targeting moieties
EP3129402A4 (en) 2014-04-08 2017-12-13 University Of Georgia Research Foundation, Inc. Site-specific antibody-drug glycoconjugates and methods
EP3154574B1 (en) * 2014-06-12 2022-05-11 CSPC Megalith Biopharmaceutical Co., Ltd. Homogenous antibody drug conjugates via enzymatic methods
SG10202002153PA (en) 2014-10-09 2020-05-28 Genzyme Corp Glycoengineered antibody drug conjugates
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
JP7042816B2 (ja) 2016-11-08 2022-03-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド レプチン受容体をアンタゴナイズする抗原結合性タンパク質
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
GB201717446D0 (en) * 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
US11834500B2 (en) 2017-12-18 2023-12-05 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
AU2019249273A1 (en) 2018-04-06 2020-10-15 Regeneron Pharmaceuticals, Inc. Methods of treatment using a leptin receptor agonist antibody
JP1640846S (el) * 2018-10-16 2019-09-09
CN112867732A (zh) 2018-11-21 2021-05-28 瑞泽恩制药公司 抗葡萄球菌抗体和其用途
BR112021012233A2 (pt) 2018-12-21 2021-09-08 Regeneron Pharmaceuticals, Inc. Análogos de rifamicina e conjugados de anticorpo-fármaco dos mesmos
MX2021008958A (es) 2019-02-01 2021-11-04 Regeneron Pharma Proteínas de unión a antígeno del receptor gamma anti-il2.
EP3947441A1 (en) * 2019-03-27 2022-02-09 UMC Utrecht Holding B.V. Engineered iga antibodies and methods of use
EP4146686A2 (en) 2020-05-08 2023-03-15 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
WO2022060827A2 (en) 2020-09-15 2022-03-24 Regeneron Pharmaceuticals, Inc. Use of lepr agonists for pain
KR20220052098A (ko) 2020-10-20 2022-04-27 주식회사 엘지에너지솔루션 마스킹 테이프를 이용한 전극 시편에 대한 물성 측정 시스템 및 이를 이용한 물성 측정 방법
KR102576252B1 (ko) * 2021-04-07 2023-09-11 아주대학교산학협력단 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물
WO2023069711A1 (en) * 2021-10-22 2023-04-27 Trustees Of Tufts College Fap-targeted neutron capture agents, and uses and formulations related thereto
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
US20240052051A1 (en) 2022-07-29 2024-02-15 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
WO2024026494A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
WO2024098002A1 (en) 2022-11-04 2024-05-10 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024107759A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CN1173878A (zh) 1995-10-16 1998-02-18 尤尼利弗公司 双功能或双价抗体片段类似物
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
WO1998005787A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1487879B1 (en) 2002-03-01 2012-12-26 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
EP3150630A1 (en) 2002-09-27 2017-04-05 Xencor Inc. Optimized fc variants and methods for their generation
JP4768439B2 (ja) 2002-10-15 2011-09-07 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
JP4629047B2 (ja) * 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
US8399618B2 (en) * 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP2154157A3 (en) 2004-01-12 2010-04-28 Applied Molecular Evolution Inc. FC region variants
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
AU2005289594B2 (en) * 2004-09-27 2012-02-02 Centocor, Inc. Srage mimetibody, compositions, methods and uses
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
RU2007145509A (ru) * 2005-05-09 2009-06-20 Гликарт Биотехнологи Аг (Ch) Антигенсвязывающие молекулы, имеющие модифицированные fc-участки и измененное связывание с fc-рецепторами
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
JP2009504569A (ja) 2005-06-30 2009-02-05 セントカー・インコーポレーテツド 向上した治療活性をもつ方法および組成物
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8460364B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
EP2125893A2 (en) * 2007-01-23 2009-12-02 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2009130198A2 (en) * 2008-04-21 2009-10-29 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
CN112812184A (zh) * 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UY34317A (es) * 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß

Also Published As

Publication number Publication date
RS57748B1 (sr) 2018-12-31
WO2014043361A1 (en) 2014-03-20
CL2015000606A1 (es) 2015-11-13
AU2013315499B2 (en) 2018-08-09
PH12015500528A1 (en) 2015-05-04
EA035987B1 (ru) 2020-09-09
CA2884762C (en) 2022-07-19
LT3366705T (lt) 2023-07-25
EP3366705B1 (en) 2023-05-03
TN2015000085A1 (en) 2016-06-29
DOP2015000050A (es) 2015-04-15
CY1120909T1 (el) 2019-12-11
IL276866B (en) 2021-10-31
PT2895513T (pt) 2018-10-08
EP2895513A1 (en) 2015-07-22
CA2884762A1 (en) 2014-03-20
KR102426488B1 (ko) 2022-07-28
KR20150054931A (ko) 2015-05-20
CN110590953A (zh) 2019-12-20
CN104797601A (zh) 2015-07-22
JP2015533490A (ja) 2015-11-26
ES2950509T3 (es) 2023-10-10
SG10201701831VA (en) 2017-05-30
PL3366705T3 (pl) 2023-09-18
IL271027B (en) 2020-09-30
PE20150650A1 (es) 2015-05-26
IL237640B (en) 2019-12-31
EP4223783A2 (en) 2023-08-09
MA37949B1 (fr) 2017-07-31
PL2895513T3 (pl) 2018-11-30
ECSP15014133A (es) 2017-02-24
MA37949A1 (fr) 2016-05-31
KR102185151B1 (ko) 2020-12-01
EP2895513B1 (en) 2018-05-23
EP3366705A1 (en) 2018-08-29
EA202091166A1 (ru) 2021-04-30
DK2895513T3 (en) 2018-09-03
IL286766A (en) 2021-10-31
AU2013315499A1 (en) 2015-04-02
EA201590545A1 (ru) 2015-08-31
SI2895513T1 (sl) 2018-11-30
IL276866A (en) 2020-10-29
SG11201501521TA (en) 2015-03-30
HRP20181354T1 (hr) 2018-10-19
CN104797601B (zh) 2019-08-30
EP4223783A3 (en) 2023-11-15
HUE062876T2 (hu) 2023-12-28
UA116995C2 (uk) 2018-06-11
MX366103B (es) 2019-06-27
CR20150147A (es) 2015-05-29
MY170126A (en) 2019-07-05
MX2015003234A (es) 2015-11-16
KR20200136044A (ko) 2020-12-04
FI3366705T3 (fi) 2023-07-28
HUE039337T2 (hu) 2018-12-28
HRP20230623T1 (hr) 2023-09-29
SI3366705T1 (sl) 2023-08-31
ES2684549T3 (es) 2018-10-03
RS64317B1 (sr) 2023-08-31
IL237640A0 (en) 2015-04-30
MX2019007753A (es) 2019-09-09
NZ705983A (en) 2018-06-29
PT3366705T (pt) 2023-07-19
IL271027A (en) 2020-01-30
DK3366705T3 (da) 2023-07-31
LT2895513T (lt) 2018-09-10
KR20220110855A (ko) 2022-08-09
JP6438397B2 (ja) 2018-12-12
BR112015005352A2 (pt) 2017-08-08
ZA201501417B (en) 2016-12-21

Similar Documents

Publication Publication Date Title
IL286766A (en) fc-containing polypeptides with variable glycosylation and reduced effector function
HK1217731A1 (zh) 異源二聚化多肽
HK1210790A1 (en) Modified factor polypeptides and uses thereof
HK1207665A1 (en) Polypeptides having transgalactosylating activity
EP2725642A4 (en) LITHIUM, MANGANE AND NICKEL CONTAINING SPINELL MIXED OXIDE
EP2901512A4 (en) SEALING ELEMENT AND BATTERY THEREOF
PT2855506T (pt) Péptido e utilização do mesmo
HK1211042A1 (en) Inflammation-enabling polypeptides and uses thereof
EP2820034A4 (en) MODIFIED ADIPONECTINPOLYPEPTIDES AND ITS USES
HK1201050A1 (en) Polypeptides and their use
ZA201504462B (en) TGFß-DERIVED POLYPEPTIDES AND USES THEREOF
AU2012901619A0 (en) Fusion Proteins and Use Thereof
GB201204065D0 (en) Fusion polypeptide